• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:

    公开号:SU1246895A3
    申请号:SU833653375
    申请日:1983-10-17
    公开日:1986-07-23
    发明作者:Бернард Кадин Саул；Сарджес Рейнхард
    申请人:Пфайзер Инк (Фирма)；
    IPC主号:
    专利说明:

    3. The method according to p. 1, about t l and h a-yu B; and with the fact that the acylation is carried out at a molar ratio of alkanoic anhydride and 4-amino compound from 4: 1 to 25: 1, respectively.
    The invention relates to a process for the preparation of derivatives (152,4) of triazole (4,3-a) quinoxalin-4-ymine of PCHI of their salts, which have antidepressant activity and can be used in meditdan.
    The purpose of the invention is a method for producing derivatives (152eA) of triazole (4,3-) quinoxalin-4 amine with anti-depressant activity.
    Example 1, 4-Methylamino (1,2,) triazole (453-a) quinoxaline,
    4-Chlorine (152.4) triazole (453-a) quinok-saline (2.0 g; 0.01 mol) in 30 ml of M, N-dimethylformamnd is saturated with monomethylamine gas and stirred at room temperature for 3 hours. Monomethyl gas is again bubbled through the solution, which is stirred at room temperature for another 2 hours. The precipitate is separated by filtration and washed with methylformamide. After recrystallization from NN-dimethylformamide, 1 e37 g (sample 69%) 4 - methylamino (1 e 2 4) triazole ( 4J 3-c1) quinoxaline5 t, pl Bbfflte 300 s.
    Mass spectrum: m / e 199 (P).
    Calculated D: C 60,, 29; H 4.55; N 38.15. WITH,. N „M
    ten
    .E 5Found: C 59.99; H 4.47;
    N 35.11.
    EXAMPLE 2. 4-D: methylamine 1 (15: 2.4) triazole (4,3-a) quinoxalns.
    A suspension of 2.0 g (0.01 mol) of 4-chloro- (1.254) triazral (4,) quinoxylin in 30 ml of H, N-dimethylformamide is saturated with gaseous dimethylamine and stirred at room temperature overnight. This mixture was poured onto ice, and the precipitate was removed by filtration. When recrystallization
    4. The method according to claim 1 and 1 and the fact that the halogenated hydrocarbon solvent is in the acylation reaction with an inert non-aqueous organic solvent.
    640 mg (yield 44%) of 4-dimethylamino (1,2,4) triazole (4, 3-a) quinoxaline, m.p. 1 84-186 C.
    Mass spectrum; m / e 213 (P). Vyagisleno,%: C, 61.96; H 5.20;
    N 32.84. S., H ,, NJ Found,%: C 62.26 | H 5.43,
    N 32.92.
    Example 3, 4 Ethylamino (1,2, 4) triazole (4,3-a) quinoxaline.
    A suspension of 2.0 g (0.01 mol) of 4-chloro (1,2,4) triazole (4,3-a) quinoxalic in 30 ml of N, N-dimethylforma JIda is saturated with mono-ethylamine gas and stirred at room temperature for 2 hours. Mono-ethylamine gas is bubbled through the mixture again and stirring is continued for 2 hours. The precipitate is removed.
    by filtration and washed with M, methylformamide. Recrystallization from methanol gives 680 mg (yield 32%) of 4-ethylamino (1.2.4) triazole (4.3 - Coxinocaline, mp 254-25b. Mass spectrum: m / e 213 (P ), Calculated,%: C 61.96; H 5.20; N 32.84. C ,, H Nj Found,%; C 61.93; H 5.09; N 32.72 „
    PRI me R 4. 4-Dimetsch1amino (15 25 i) triazole (4,3-a) quinoxaline.
    4-Hpor (1,2,4) triazole (4.3-0) quinoxaline (4.4 g; 0.021 mol), product 2, mixed with 6.5 ml (0.063 mol) of diethylamine in 100 ml of N, N -dimethylformamide at room temperature for 2 hours, the reaction mixture is poured into a mixture of ice-water and a crude product is obtained in a wilting cake, which is subsequently filtered and washed with water. With
    recrystallization from isopropanol yields 3.36 g (yield 66%) of 4-di-; ethylamino (1,2,4) triazole (4,3-c) quinoxaline, so pl. 117 - 119 C.
    Mass spectrum: m / e 241 (P).
    Froze 4-Di-n-propshtami-, but (1,2,4) triazole (4,3-a) quinoxaline.
    4-Chlorine (, 4) triazole (4,3-th) quinok- (2.0 g; 0.01 mol), the product of example 2 and 3.0 g (0.03 mol) of di-H-propylamine in 50 ml of N, N-dimetshtm-forgmid are stirred at an appropriate temperature for 3 hours. This solution is poured onto ice to form a precipitate, which is separated by filtration and air dried. Recrystallization from 250 ml of cyclohexane yields 1.1 g (yield 41%) of di-propyl ai-niHo (1,2,4) triazole (4,3-e) quinoxaline, m.p. 240 - 242 ° C.
    m / e 259 (P). : C, 66.89; H 7.11; N 26.00. C ,, H, gNj
    Found,%: C 66.68; H 6.97; N 26.12.
    4-Isopropylamino (1 2.4) triazole (4, 3-o) quinoxaline.
    4-Chloro (1,2,4) triazole (4, 3- (s) quinoxaline (2.0 g; 0.01 mol), product of example 2 and 1.77 g (0.03 mol) of isopropylamine in S, H-dimethylformamide (30 ml) is stirred at room temperature overnight. The dark solution is poured on -the precipitate formed is separated by filtration and washed with water.The crude product is recrystallized from ethanol and then twice from isopropyl ether. 53% yield) 4-isopropylamino (1,2,4) triazole (4,3-a) quinoxaline, mp 133-135 C.
    Mass spectrum: m / e 222 (P). N1,%: C 61.79; H 5.90; N 30.02.
    Mass spectrum: Calculated,%
    PRm e R 6,
    C ,, H, 3N5-1 / 3 jQ,
    Found,%;
    C, 61.51; H 5.89; N 29.90.
    EXAMPLE 7. 4-Diethyl ino-1 -methyl (1,2,4) triazole (4,3-a) quinoxaline.
    This compound was prepared analogously to example 11, using 4-chloro-1-methyl (1, 2.4) triazole (4,3-a) quinoxaline (the procedure of example 3) instead of 4-chloro (1.2 , 4) triazole (4,3-a) quinoxaline (product of example 2) and diethylamine as

    20
    25
    2468954
    $ Agent instead of di-M-propi-pamina. The crude product obtained is recrystallized from chloroform and then from cyclohexane. Obtain 7.2 g (yield of 54%) of pure 4-diethylamino-1-methyl (1,2,4) triazole (4,3-a) chinoxaline, so pl. 123 -. , Example 8. 4-Amino-1-ethyl (1, 2.4) triazole (4,3-a) quinoxaline. 10 Ammonia gas was bubbled through a solution of 1.2 g (0.005 mol) of 4-chloro-1-ethyl (1,2,4) triazole (4, 3-c |) inoxoxalin (product of example 4) in 20 ml of S , M-dimethylformamide at J5 about 2 minutes. The solution was stirred at 0 ° C for 30 minutes and 1 hour at room temperature. Then the reaction mixture is poured onto ice n first.
    Mix for 20 minutes. The precipitate formed is separated by filtration, washed with water and air dried. When recrystallization from ethanol, 220 mg (yield 22%) of pure 4-amino-1-ethyl (1,2, 4) triazole (4,3-) quinoxaline are obtained, mp 284-248 ° C.
    Mass spectrum: m / e 213 (G).
    Blyisleno, 5: C, 61.10; H 5.28; N 32.39. C ,, N ,, NJ- 1/6 N, 0
    Found,%: C 61.36; H 5.14; N 31.96.
    Example 9. 4-Methylamino-1- -ethyl (1, 2.4) triazole (4,3-c) quinoxaline.
    Monomethylamine gas is bubbled through a solution of 4-chloro-1-ethyl (1,2,4) triazole (4,3-a) quinoxy salt (1.2 g; 0.005 mol), the product of example 4, in 50 ml of dimethylformamide at About C for 2 minutes The reaction mixture is stirred at 30 MIH at 2 hours at room temperature, then poured onto ice and stirred for an additional 20 hours. The precipitate formed is separated by filtration, washed with water and air dried. After recrystallization from ethanol, 1.0 g (yield 88) of 4-methyl-amino-1-methyl (1,2,4) triazole (4,3-c1) cinoxalin is obtained, m.p. 271-273, p. 50 Mass spectrum: m / e 227 (P).
    Calculated,%: C, 62.80; H 5.82; . N 30,51.
    thirty
    45
    C ,,, H, jN
    -1/8 5.86;
    Found,%: C 62.72; H 55N 30.62.
    Example 10. 4-Dimethylamino-1-, ethyl (1,2,4) triazole (4,3-o) quinoxalin.
    512А68956
    4-Chloro-1-ethyl (1,2,4) triazole (4, (69% codecode) of pure 4-diethylamino-1-. 3-o) chinoxaline (1.2 g; 0.005 mol), ethyl (1 , 2,4) triazole (4,3-L) (quinoxali- product of lenmer 4 and 676 mg (0.015 mol) of anhydrous dimethylamine in 50 ml of N, N-dimethylformamide rempegogram at 30 minutes and at room temperature for 2 Part of the reaction mixture of vyparot on ice and peremeniigivayut 20 minutes.
     is separated by filtration, washed with 10 254) triazole (453-c ") quinoxaline (2.3 rj and dried in air. At 0.01 mol), the product of example 4, in recrystallization from chloroform and ZO w N, N-dimethylpop Mamida. A precipitate formed through the mixture of chloroform and cyclohexo. Then, 510 mg (yield 42%) of the reaction mixture was stirred for 4-dimethylamino-1-ethyl (1,254) treyazole 15 overnight at room temperature. Osan in the form of a white solid,
    m.p. 98-100 C.
    Mass spectrum: m / e 269 (P),
    PRI and e R 13. 4-Isopropyl-1
    -ethyl (1., 2, 4) triazole) (H, 3rd) quinoxaline Isopropylamine (1.77 g; 0.03 mol)
    4-chloro-1-etsh1 (1j
    (4,3-с) quinoxaline, t „pl" 155-158 С, Mass spectrum: m / e 241 (p). Vyisleno,%: C 64.7 / 1; H 6.27; N 29.02. C.H.jNy
    25
    Found,%: C 64.69; H 6.27;
    N 29.32.
    Example 11, 1-Etsh1-4-ethylamino (1,2,4) triazole (4.3-0) quinoxalines
    Monoethylamine is bubbled through a solution of 4-chloro-1-ethyl (1,2,4) triazole (4.3 - ") quinoxaline (2.1 g, o, 005 mol) of the product of example 4, in 50 ml N of N-dimer tilformamide at 0 ° C for about 2 minutes. The clear solution is stirred at 30 minutes and at room temperature for 2 hours. Then the reaction mixture is poured onto ice and the precipitate is filtered by filtration, the prodol is separated by filtration and washed with K, dimethylformamide. When recrypted from ethanol, 1.6 are obtained g (yield 6.3%) 4-isopropylamino-1-ethyl (1, O 2.4) triazole (4,3-a) quinoxaline, t. pl. 222-224 ° C.
    Mass spectrum: m / e 255 (P). Calculated,%: C 65.86; H 6.7G, N 27.43.
    C ,, H ,, N,
    Found,%: C 65,32; H 6.76; N 27.25.
    PRI me R 14. 4-Ethylamino-1- -isopropyl (1,2,4) triazole (4,3-a) quinoxaline.
    A suspension of 1.0 g (0.004 mol) of 4- -chloro-1-isopropyl (1,2,4) triazole (4, 3-) quinoxaline (product of example 6) in 15 ml of N, N-dimethylformamide is washed with water and dried on 35 is emitted with gaseous monoethylamine. When recrystallized from ethanol and stirred at room temperature, 1, O g (yield 83%) of the pure pot is obtained for 4 hours. The precipitate is 1-ethyl 4-ethylamino (1., 2.4 ) triazole (4z 3-a) quinoxaline in the form of a white solid, so pl. 235-238 0.
    Mass spectrum; m / e 241 ().
    Calculated,%: C 64.71; H 6.27;
    are filtered by filtration and washed with N, N dimethylformamide. 220 mg (yield 22%) of 4-ethylamino-1- -isopropyl (1,2,4) triazole (4,3-d) quinoxaline are obtained, t, mp, 209-211.c.
    N 29.02.
    Found,%: C 64.57; H 6.20; N 29-, 15,
    PRI me R 12. 4-Diet1 lamino 1- -ethyl (1,2,4) triazole (4,3-a) quinoxaline
    This compound was prepared analogously to example 11, using 4-chloro-1-β-e-1 (1,2,4) triazole (4,3-a) quinoxaline (product of example 4) as the starting material instead of 4-chloro (1,2, 4) three azole (4,3-Q) xynoxaline (product of example 2) and dicylamine as a pit gate instead of di-n-propylamine. The crude product is recrystallized from cyclohexane. .and get 3.54 g
    (69% off code) of pure 4-diethylamino-1-ethyl (1,2,4) triazole (4,3-L) (quinoxali-
    254) triazole (453-c «) quinoxaline (2,3 rj 0.01 mol), product of example 4, in the ZO N, N-dimethylpop mamide. A precipitate formed after 3 min. Then the reaction mixture was stirred overnight at room temperature. Osan in the form of a white solid,
    m.p. 98-100 C.
    Mass spectrum: m / e 269 (P),
    PRI and e R 13. 4-Isopropyl-1
    -ethyl (1., 2, 4) triazole) (H, 3rd) quinoxaline Isopropylamine (1.77 g; 0.03 mol)
    4-chloro-1-etsh1 (1j
    the dock was separated by filtration and washed with L, K-dimethylformamide. When recrystallized from ethanol, 1.6 g (6.3% yield) of 4-isopropylamino-1-ethyl (1, 2.4) triazole (4.3 -a) quinoxaline, m. pl. 222-224 ° C.
    Mass spectrum: m / e 255 (P). Calculated,%: C 65.86; H 6.7G, N 27.43.
    C ,, H ,, N,
    Found,%: C 65,32; H 6.76; N 27.25.
    PRI me R 14. 4-Ethylamino-1- -isopropyl (1,2,4) triazole (4,3-a) quinoxaline.
    A suspension of 1.0 g (0.004 mol) of 4- -chloro-1-isopropyl (1,2,4) triazole (4, 3-) quinoxaline (product of example 6) in 15 ml of N, N-dimethylformamide is saturated with mono-ethylamine gas and stirred at room temperature for 4 hours. Sediment.
    Remove monoethylamine gas and stir at room temperature for 4 hours. Precipitate.
    are filtered by filtration and washed with N, N dimethylformamide. 220 mg (yield 22%) of 4-ethylamino-1- -isopropyl (1,2,4) triazole (4,3-d) quinoxaline are obtained, t, mp, 209-211.c.

    Mass spectrum: m / e 255 ().
    The filtrate is then poured onto ice, the precipitate is filtered by filtration, washed with water, recrystallized from methanol and then from isopropanol, and an additional 200 mg (yield 20%) of pure 4-sodium-1-amino-1-propyl (1.2%) is obtained. , 4) triazole (4, 3-p) quinoxaline, so pl. 210-211 ° C.
    Calculated,%: C 65.86; H 6.71;
    N 27.43.
    C, 4H ,, N
    Found,%: C 65.53; H 6.58; . N 27.29.
    7
    Example 15. 4-Dimethylamino--1-isopropyl (1,2,4) triazole (4, 3-a) chioxapine.
    4-Chloro-1-eopropyl (1,2,4). Triazole (4,3-) kinoksalin (1.0 g, 0.004 mol) the product of example 6 and 900 mg (0.012 mol) of diethylamine in 15 ml of M, L- dimethylformamide and stirred at room temperature for 4 hours. The reaction mixture is drunk on ice and the precipitate is separated by filtration, rinsed with water and placed in a column with 175 ml of silica gel and finally eluted with chloroform. The eluent is evaporated in vacuo to obtain 850 mg (75%) pure 4-ethylamino-1-isopropyl (1,2,4) triazole (4,3-C1) quinoxaline in the form of a white solid, m.p. 93-95 S.
    Mass spectrum: m / e 283 (P).
    Then the pure product (100 mg) is distilled in vacuum (0.1 mm Hg at 140-150 ° C. An analytical sample (80 mg) is obtained from t. 94-96 ° C
    Calculated,%: C 67.82; H 7.47; N 24.71. C, 6H ,, Ns.
    Found,%: C 67.56; H 7.20; N 24.50.
    Example 16. 4-Diethylamino-1, -I-propyl (1,2,4) triazole (4,3-a) quinox saline.
    4-Chloro-1-n-prop1 (1,2,4) triazole (4,3-c () quinoxaline (1.23 gJ0.005 mol) is the product of example 5 and 1.1 g (0.00t5 mol) of diethylamine in 15 ml of N, N-dimethylformamide is stirred at room temperature for 2 hours. Then the reaction mixture is taken up in ice. The precipitate is separated by filtration, washed with water and dried in air. After double crystallization from aqueous ethanol, 1.1 g are obtained (yield 78%) of pure 4-diethylamino-1- -H-propyl (1,2,4) triazoleX4, 3-a) quinoxaline, mp 92-94 ° C.
    Mass spectrum: m / e 283 (P).
    Calculated,%: C, 67.28; H 7.50; N 24.52. C ,, H, N.1.8 N, 0
    Found,%: C 67.38; H 7.45; N 24.73.
    PRI me R 17. 8-Chloro-4-diethyl-amino-1-ethyl (1,2,4) triazole (4,3-th) quinoxalin.
    ,but. Preparation of 4,8-dichloro-1- -ethyl (1,2,4) triazole (4,3-a) quinoxal468958
    on. 1.0 g of 2,6-dichloro-3-hydrazinchino; c-, saline (0.0044 mol), product of stage a, preparation M, are refluxed with 15 ml of three to 5 ethyl orthopropionate for 4 hours
    and cooled to room temperature. The precipitate is separated by filtration, washed with cyclohexane and dried in air. 730 mg is obtained (yield 62%)
    10 4,8-dichloro-1-ethyl (1,2,4) triazolol (4,3-) cinoxaline. m.p. vsch1e 250 C. Mass spectrum: m / e 266 (P), m / e 268
    (P + 2). b. Preparation of 8-chloro-4-diethyl15 amino-1-ethyl (1,2,4) triazole (4,3-a) quinoxalin. 4,8-Dichloro-1-etsh1 (1,2,4) triazole (4,3-a) chinoxaline (7.4 g; 0.028 mol) and 6 g (0.082 mol) of diethylamine in 150 ml N, M-dimethylformami20 yes, it is stirred at room temperature for 4 hours. The reaction mixture is filtered and the filtrate is poured onto ice. The precipitate is separated by filtration and dissolved.
    25 in chloroform. The chloroform phase is successively dried over anhydrous magnesium sulphate, filtered and then evaporated in vacuo to give yellowish hard product, which after
    0 Recrystallization from a mixture of diethyl ether and petroleum ether gives 1.6 g of pure 8-chloro-4-diethyl-. amino-1-ethyl (1,2,4) triazole (4, 3-d) quinoxaline, T.PL. 105-108 C (with different).
    5 (Mass spectrum: m / e 303 (P), m / e 305. - (P + 2).
    Calculated,%: C 59.3; H 5.97;
    N 23.05.
    0C, 5H, aClN,
     Found,%: C 58.9: 2, H 5.85,
    N 22.81.
    Example 18. 7,8-Lichloro-4-diethylamino-1-ethyl (1,2,4) triazole (4,3, -a) quinoxaline.
    Preparation of 2,6,7-trichloro-3-hydroxy-raznichinoksalina.2,3,6,7-tetrachlorochinoxalin (4.4 g; 0.016 mol) and 1.76 g (0.035 mol) hydrazine hydrate in 60 ml ethanol is stirred over night at room temperature. The thick suspension is filtered and washed with ethanol. 4.9 g of crude 2,6,7-trichloroquinoxaline are obtained, m.p. below 260 C. Mass spectrum: m / e 262 (P), m / e
    264 (P + 2).
    Preparation of 4.7, B-trichloro-1- -ethyl (1,2,4) triazole (4,3-a) quinoxaline-. 4.9 g of 2,6,7-trichloro-3-hydrazine-hinoxaline (0.018 mol) in 50 ml of three ethyl orthopropionate is heated at 100 ° C for 2 hours. The precipitate formed is separated by filtration at room temperature and washed with cyclohexane. After double recrystallization from a mixture of chloroform and cyclohexane, 2.9 g (yield 54%) of pure 1,7,8-trichloro-1-α-ethyl (1,2,4) triazole (4,3-a) quinoxapine are obtained. as a pink solid, mp 198–201 ° C.
    Mass spectrum: m / e 300 (P) J 302 ..
    (P-2); 306 (P + 6X.
    Preparation of 7,8-dichloro-4-diethyl amino-1-ethyl (1,2,4) triazole (4,3-) inoxoxalin. 4.7.8-Trichlo, p-1-ethyl (1, 2.4) triazole (4,3-a) quinoxaline (2.9 g 0.0096 mol) and 2.1 g (0.0388 mol) diethylamine in 50 ml of N, N-dimethioformida is stirred at room temperature at 2 hours. The reaction mixture is drunk on ice and stirred for 15 minutes. The precipitate is separated by filtration, washed with water and dried in air. After three-fold recrystallization from isopropanol, 500 mg (yield 16% pure 7, B-dichloro-4-diethylamino-1-α-ethyl (1, 2.4) triazole, (4,3-a) hinoxaline, 147-149 are obtained ° s
     Mass Spectrum: m / e 337 (P), 339 (P + 2),
    C 53.26; H 5.07; N 20.70. C. Found,%: C 53.05; H 5.13,
    N 20.75.
    Example 19. 4-Diethylamino-1- -ethyl-8-methoxy (1,2,4) triazole (4,3-a; quinoxaline.
    ; but. Preparation of 2-chloro-3-hydrazine-6-methoxyquinoxaline. 2,3-Dichloro-6-methoxyquinoxaline (4.2 g; 0.018 mol), product of stage 5, preparation D and 2.7 ml of hydrazine hydrate in 100 ml of ethanol are heated under reflux for 4 hours and stirred. Wash at room temperature overnight. The precipitate is separated by filtration and washed with ethanol. 3.9 g (yield 97%) of 2- -chloro-3-hydrazin-6-methoxnhinoxaline are obtained, m.p. below 250 ° C
    Mass spectrum: m / e 224 (); 226 (P + 2).
    .
    Calculated,%:
    ten
    15
    25
    thirty
    35
    45
    50
    55
    b. Preparation of 4-chloro-1-eth1- -8-methoxy (15254) triazole (4,3-a) chinoxalin.2-Chloro-3-hydrazin-6-methoxy-xinoxaline (1.3 g; 0 , 0058 mole)
    and 25 1-W of triethyl orthopropionate is heated at 100 ° C for 4 hours and stirred at room temperature for 60 hours. The precipitate is separated by fritting and washed with ethanol. After recrystallization from ethanol, 530 mg (yield 35%) of pure 4-chloro-1-ethyl-8-methoxy (1,2,4) triazole (4., 3-a) quinoxaline are obtained, m.p. 196-19 s (with decomp.).
    Mass spectrum: m / e 262 (), 264 (P + 2).
    V.Preparation of 4-diethylamino-1- -ethi1-8-methoxy (1,2,4) triazod (4,3-a) quinoxagna „4-chloro-1-ethyl-8-me20 tox (1,2, 4) triazolol (4,3-a) xynoxaline (520 mg, 0.002 mol)) and 673 mg (0.008 mol) of diethylamine in 10 ml of N5N-dimethylformamide are stirred at room temperature overnight. The reaction mixture is poured onto ice, the precipitate is separated by filtration, washed with water and dried on air. After recrystallization from diethyl ether and petroleum ether, 140 mg (yield 23%) of pure 4-diethylamino-1-ethyl-8-methoxy (1,2,4) triazole (4,3-c1) quinoxalkane are obtained. m.p. 135-138 C.
    Mass spectrum: m / e 299 (). Calculated,%: C 63.71; H, 7.10;
    40
    N 23.22. C.6 N ,,
    1/8
    Found,%: C 63.63; n 6.88, n 23.37.
     PRI me R 20. 4-Diethylamino-1- -fenschg (1 ,, 2.4) triazole (4.3-0) quinoxaline. - -.
    Preparation of 4-chloro-1-phenyl (1,2, 4) (4,3-a) quinoxaline. 2-Chloro-3-hydrazinquinoxaline (2.2 g; 0.011 mol) is mixed with 6 ml of triethyl ortho-benzog | t and heated at 100 ° C for 30 minutes. After cooling the orange mixture to room temperature, ethanol is added. After filtration of the resulting precipitate, 2,1 g of the crude product is distilled off, which is further purified by trituration with warm methanol and thereafter. filtering. After air drying, 1.58 g (51% yield) of pure 4-chloro-1-phenyl (1,2,4) are obtained.
    eleven
    triazole (4, 3-) quinoxaline as an orange solid ..
    Preparation of 4-diethylamino-1-phenyl (1,2,4) triazole (4,3-c1) quinoxaline K 1.58 g (0.00563 mol) 4-HLOR-1-phenyl (1,2,4) triazole (4,3-a) quinoxaline dissolved in 15 ml of H, M-dimethylformamide, 1.738 ml of diethylamine are added. This mixture is stirred overnight at room temperature. The precipitate formed was separated off by filtration and washed with N, N-dimfiTiylformamide and recrystallized twice from a mixture of hexane and ethyl acetate (3: 1 by volume). 555 mg of pure 4-distilla no-1-phenyl (1,2,4) triazole (4, 3-c |) quino saline are obtained in the form of white needles, mp.166tes c.
    Absolutely,% - C .71.60, H 5.99; N 22.06.
    C.
    Found,%: C 71.86; H 5.86, N 22.09.
    EXAMPLE 21. 4-Distilamino-1-β-trifluoromethyl (1,2,4) triazole (4,3-hl) quinoxalin.
    Preparation of 4-hydroxy-1-trifluoromethyl (1,2,4) triazole (4,3-e) quinoxaline. 2-Chloro-3-hydrazinhinoxaline (3.89 g; 0.02 mol), the product of example 1, is added to 22.8 g (0.20 mol) of cold trifluoroacetic acid (15.4 ml) contained in a calcined dry reaction flask immersed in an ice bath. The mixture is in a dry nitrogen atmosphere with mechanical stirring. Then the reaction mixture is heated to 100 ° C for 3 hours and poured onto ice. The resulting product is then collected by suction filtration, washed with water and dried in air to constant weight. Thus, 3.0 g (60%) of pure 4-hydroxy-1-trifluoromethyl (1,2,4) is finally obtained. triazole (4.3-0) quinok-salina, so pl. above .
    Mass spectrum: m / e 254 (P). . Preparation of 4-chloro-1-trifluoromethyl (1,2,4) triazole (4.3-0) quinoksali-. on. In a dry calcined co-pbu in a dry gas atmosphere, 3.0 g (0.0188 mol) of 4-oxy-1-trifluoromethyl (1,2,4) triazol (4.3 -) quinoxaline and 30 ml are placed. phosphorus oxychloride in 2.38 g (0.0236 mol) of triethylamine (3.3 ml). Reaction mixture
    46895.12
    heated at about 16 h. After completion of this stage, the spent mixture is cooled to room temperature, K-concentrated in vacuo and 5 distributed between ice, water and ethanol, and then extracted with ethyl acetate. The extract is then washed with saline solution and dried over anhydrous sulphate.
     About magni. After removing the drying agent by filtration and the solvent by evaporation under reduced pressure, a residue is obtained, which is subsequently dissolved
    5 in hot chloroform and filtered. This filtrate was incubated overnight at room temperature. i uo) - and again filtered. The final filtrate is concentrated in vacuo and receive
    20 g of 4-chloro-1-trifluoromethyl (1,2,4) triazole (4,3-a) quinoxaline in the form of a brownish-colored solid.
    5 Preparation of 4-diethylamino-1-trifluoromethyl (1, 2.4) triazole (4,) quinoxaline. A mixture containing 700 mg (0.0025 mol 4-chloro-1-trifluoromethyl 11,2,4) trnazole (4, H-a) quinoxaline 0 (prepared as described} 1o), 560 mg (0.0075 mol) of diethylamine (0.8 ml) and 10 ml of N, N-dimethylformamide, stirred at room temperature overnight and then poured onto
    5 ice The resulting mixture was filtered, the solid that was removed was washed with water and dissolved in ethyl acetate. The organic is then dissolved with all salt solution and dried over anhydrous magnesium sulphate. After drying agent by filtration and gel solution by evaporation under reduced pressure, a light yellow solid is obtained.
    5 a substance that, after recrystallization from diethyl ether, gives pure 4-diethylamino-1-trifluoromethyl (1,2,4) triazole (4,) quinoxaline. The output of the first fraction melts at
    155 -, makes 260 mg
    (34%), and the yield of the second fraction, melting at 153-156 ° C, is 170 mg (22%).
    A, 56;
    Calculated,%: C 54.37; H N 22.64. C 1., H, FjNj
    Found,%; C, 54.08; H 4.47; N 23.32.
    13
    EXAMPLE 22 4-Isopropylamino-1-trifluoromethyl (152.4) triazole (4, 3-o) quinoxaline. A mixture containing 700 mg (0.0025 mol) 4-chloro-1-trifluoromethyl (1,2,4) triazole (4,3-a) quino-salna and 443 mg (0.0075 mol) is (0.64 ml) in 10 ml of N, N-flH methylformamide, stirred at room temperature overnight and then poured onto ice. The mixture is filtered, the solid that is separated is washed with water and dissolved in diethyl ether. This ethereal solution is washed with brine and dried over anhydrous magnesium sulphate. After removing the drying agent by filtration and the solvent by evaporation under reduced pressure, a white powder is obtained, which, after 20 ether, gives 520 mg (82%) of pure
    a single recrystallization from diethyl ether gives 550 mg (74%) of the pure 4-isopropylamino-1-trifluoromethyl (1,2, 4) triazole (4,) quinoxaline, tl 185-187 ° C.
    Calculated,%: C, 52.88; H 4.10; N 23.72.
    35
    4-acetylamino-1-ethyl (1,2,4) triazole (4 3 - ") quinox; zlina, m.p. 1 93-1.
    Calculated,%: C, 61.16; H 5.13;
    Found%:
    N 27.43. C, 5H ,, N, .0
    C, 60.90; H 5.26;
    Found%
    C “H, rRZI5
    N 27.66.
    thirty
    C, 52.73; H, 4.00; N 23.67,
    Example 23. 1-eth1-4- (M-ztil
     acetylamino) - (1,2,4) triazole (4, 3-) quinoxaline. A mixture containing 241 mg (0.001 mol) of 1-ethyl-4-ethylamino (1,
    2,4) triazole (4,3-a) khinoksalnna and 2.5 g 35 with the addition of 100 mg c-dimethyl- (0.025 mol) acetic anhydride
    For example: measures 25, 4-diacetylamino-ethyl (1,2,4) triazole (4.3 - ") quinoxal
    A mixture containing 5.5 g (0.0258 of 4 amnno-1 - ethyl (T, 2.4) triazole (4, Zta quinoxaline and 25 g (0.25 mol) of acetic anhydride (25 ml) in 60 ml feast
    : (2.5 ml) The reaction flask in a calcined to dryness was heated under reflux at 140 ° C in an atmosphere of dry nitrogen for 3 hours and then allowed to cool to room temperature. After that, a precipitate formed, the resulting reaction mixture was poured into water and extracted with chloroform. The chloroform extracts were combined, washed with water and subsequently dried over magnesium sulfate. After removing the drying agent by filtration and solvent by ripening under reduced pressure, a solid product is obtained, which, after repeated recrystallization from a mixture of chloroform and diethyl ether, gives 160 mg (yield 57%) of 1 ethyl-55
    -4- (K-ethylacetylamino) - (1,2,4) tria-, sol (4,3-a) quinoxaline, m.p. 185 .187 S.
    aminopyridine, stirred at room temperature overnight (about 18 hours). The resulting suspension is filtered to remove insoluble material, and then the orange-red filtrate is evaporated under high vacuum to give a dark, gummy precipitate. After adding water, pinkish The white cavities that are separated by suction filtration are rinsed with: a certain amount of water and dried under vacuum at 50 ° C. I get 2p9 g (38%) of 4-diacetylamino-1-ethyl 2; 4) triazole (4, 3-a) quinoxaline, "t 155-159 ° C. Recrystallization of this material from a mixture of ethyl acetate and diethyl ether gives an analytical pure sample (mp. 158–160 ° C. A pure product is characterized using mass spectrometry and magnetic resonance in addition to elemental analysis data).
    68951
    Bcp,%: C 63.59, - H 6.05; N 24.72.
    CirH ,, NjO Found,%: C 63.17; H 6.05;
    N 24.39.
     and Mer 24. 4 Acetylamino-1-ethyl (1,2,4) triazole (4,3-p) quinoxaline,
    A mixture containing 533 mg (0.0025 mol) of 4-amino-1-ethyl (1,2,4) triazole (4,) quinoxaline and 1.0 g (0, OGmol) of acetic anhydride (1.0 ml) in 20 ml of methylene chloride are boiled under reflux overnight (about 16 hours) and then cooled to room temperature. The resulting clear solution is concentrated in vacuo and a white solid is obtained which is subsequently crystallized from a mixture of chloroform and diethyl alcohol.
    4-acetylamino-1-ethyl (1,2,4) triazole (4, 3 - ") quinox; zlina, m.p. 1 93-1.
    Calculated,%: C, 61.16; H 5.13;
    Found%:
    N 27.43. C, 5H ,, N, .0
    C, 60.90; H 5.26;
    N 27.66.
      by adding 100 mg of c-dimethyl
    For example: measures 25, 4-diacetylamino-1- -ethyl (1,2,4) triazole (4.3 - ") quinoxaline.
    A mixture containing 5.5 g (0.0258kol) 4 amnno-1 - ethyl (T, 2.4) triazole (4, Zta) quinoxaline and 25 g (0.25 mol) of acetic anhydride (25 ml) in 60 ml of pyri by addition of 100 mg of c-dimethyl
    aminopyridine, stirred at room temperature overnight (about 18 hours). The suspension obtained is filtered to remove insoluble matter, and then the orange-red filtrate is evaporated under high vacuum to give a dark, gummy precipitate. After adding water, a pinkish-white crts. tals that are separated by filtration with suction, washed with a suitable amount of water and dried in vacuum at 50 ° C. Get 2p9 g (38%) 4-diacetylamino-1-ethyl (1 2; 4) triazole (4, 3-a) quinoxaline, "t 155-159 ° C. Recrystallization of this material from a mixture of ethyl acetate and diethyl ether gives an analytically pure sample (mp. 158-160 ° C). Pure product is characterized by mass spectrometry and nuclear magnetic resonance in addition to elemental analysis data.
    15
    Mass spectrum: m / e 297 (P). Calculation,%: C, 60.59; Ы 5.09; N 23.56,. Found,%: C 60.33, H 3.09; N 23.41.
    Example 26. The following derivatives of (1,2,4) triazole (4,3-m) quinoxa-lin-4-amine are obtained using the procedures described in the preparation and examples starting from readily available materials. :
    15
    7,8-dibromo-4-diethylamino- (1,2, 4-) triazol ol (4,3-a) quinox alin, so pl. 19 9- 201 s;
    8-chloro-4-isopropylamino- (1,2, 4) griazole (4,3-c |) quinoxaline, m.p. 177-181 C:, 20
    4-ethylamino-1-trifluoromethyl- (1,2, 4) triazole (4,3-c () quinoxaline, mp. 223-
    1-ethyl-4-ethylamino-8-methoxy- (1,
    1-ethyl-4-ethylamino-8-fluoro- (1,2, 4) triazole (4,3-) quinoxaline, mp. 231–233 s;
    7,8-difluoro-4-ethylamino- (1,2,4) tri-azole (4,3-) quinoxaline, t. Pl. 208-
    4-diethylamino-8-fluoro- (1,24) triazole (4,3-a) quinoxaline, m.p. 151-153 ° C;
    4-diethylamino-1-ethyl-8-fluoro- (1, 2.4) triazole (4.3-) quinoxaline, m.p. 94-97 0;
    7-chloro-4-dimethylamino-1-ethyl- (1X, x, / -./- chloro-d-dimethylamini- I -3TMJi-v I -
    2 4) triazole (4,3-a) quinoxaline, mp.234-25 2.4) triazole (4.3 -.) Kinoxalin, methanesulfonate Smasylate), t. Pl. 214217 С
    237 ° C, 4-diethylamino-8-me-toxi (1,2,4)
    triazole (4,3-a) quinoxaline, so pl. 124- 7-; ENT-4-diethylamino-1-etsh1- (1,2
    125 C; 4) triazole (4,3-a) quinoxaline, methane 8-chloro-1-ethyl-4-isopropylamino- (1, zosulfonate, mp 172-175 C; 2.4) triazole C 4.3 -a; quinoxaline,
    35
    40
    m.p. 189-191 C;
    4- (K-piperazino) - (1,2,4) triazole (4,3-a) quinoxaline, so pl. 160-162;
     8-chlorop-4- (N-piperzino) - (1,2, 4) triazole (4,3-a) quinoxaline, mp.253-256 C;
    8-chloro-1-4- (N-H3onponmia4eTmi-amino) - (1,2,4) triazole (4,3-c) quinoxaline, m.p. 148-151 0;
    4-acetylamino-8-chloro-1-etch7- (1, 2.4) triazole (4, 3-o) quinoxaline, t. Pl. 203-205 ° C;
    - 8-chloro-1-ethyl-4- (M-isopropyl acetyl-aiAiHo) - (1,2,4) triazole (4.3-0) chinoxaline, g. square 155-158 ° C;
    , 7,8-dichloro-4- (M-isopropyl-acetyl-.mino) - (1,2,4) triazole (4,3-a) quinoxaline, t. Gsh. 207-210 С;
    4-amino-7,8-dichloro-1-ethyl- (1,2,. 4) triazole (4,) quinoxaline, m.p. above 260 ° C;
    4-amino-8-chloro-1-ethyl- (1,2,4) triazole (4, 3-c ") quinoxaline, m.p. 248-253 ° C; .
    50
    55
    7,8-dichloro-1-3 tyl-4- (N-piperazi-but) - (1,2,4) triazol ol (4,3-a) quinoxaline, methanesulfonate, t. Pl. 252-255 ° C;
    7,8-dichloro-4-dimethylamino-1-ethyl- - (1,2,4) triazole (4,3-a) quinoxalip, t. Pl. 1b8-171 C;
    7,8-dichlorop-4-dimethyl ino-1-ethyl- (1 2.4) triazole (4.3 - ") quinoxaline, methanesulfonate, t. Pl. 216-219 C;
    4-acetylamino-1-ethyl-8-fluoro- (1, 2.4) triazole (4, 3-o) quinoxaline, so pl. 203-205 sJ
    4-amino-7-chloro-1-ethyl- (1,2,4) triazole (4, 3-o) quinoxaline, methanesulfonate, m.p. 240-243 ° C;
    7-chloro-1-ztsh1-4-ethylamino- (1,2,4,) triazole (4,3-) quinox alin, methane sulfonate, t, pl. 187-189 ° C;
    7-chloro-4-diethylamino- (1,2,4) triazole (4, 3- ") quinoxaline, methanesulfonate. m.p. 205-207 0;
    . 4 diethylamino-7,8-difluoro- (1,2, 4) triazole (4,3-a) quinoxaline, methanesulfonate, t. Pl. 220-223 ° C, 4-acetylamino-758-dichloro-1-etip- (1., 2.4) triazole (4,3th |) quinoxaline, so pl. 230-232 ° C;
    ten
    15
    - 20
    -
    24689515
    8 fluoro-4 - nzopropsh1aml} Cg- i i, 2,4) triazole (4,3 - () quinoxaline, t. Pl. 215-217 C;
    4-ттно1-amino-8-fluoro- (1,2,4) triazole 5 (4,3-a) quinoxaline, t. Pl. 239-242 C;
    1-ethyl-8-fluoro-4-isoproshimo- (1,24) triazole (4.3 - ") quinoxaline, so pl. 209-212 ° C;
    7.8 difluoro-4-isopropshtamino (1,2 4) triazole (4,3-) quinoxaline, m.p. 218-221 C;
    1-ethyl-4-ethylamino-8-fluoro- (1,2, 4) triazole (4,3-) quinoxaline, mp. 231–233 s; ,
    7,8-difluoro-4-ethylamino- (1,2,4) triazole (4,3-) quinoxaline, t. Pl. 208-
    4-diethylamino-8-fluoro- (1,24) triazole (4,3-a) quinoxaline, m.p. 151-153 ° C;
    4-diethylamino-1-ethyl-8-fluoro- (1, 2.4) triazole (4.3-) quinoxaline, m.p. 94-97 0;
    7-chloro-4-dimethylamino-1-ethyl- (1 ./- chloro-d-dimethylamini- I -3TMJi-v I -
    4-25 2.4) triazole (4.3 -.) Kinoksalin, methane 2.4) triazole (4.3 -.) Kinoksalin, meth
    sulphonate Smazilat), t. pl. 214217 С
      7-; lor-4-diethylamino-1-etsh1- (1
    sulfonate, so pl. 172-175 ° C;
    7,8-dichloro-1-3 tyl-4- (N-piperazi-but) - (1,2,4) triazol ol (4,3-a) quinoxaline, methanesulfonate, t. Pl. 252-255 ° C;
    7,8-dichloro-4-dimethylamino-1-ethyl- - (1,2,4) triazole (4,3-a) quinoxalip, t. Pl. 1b8-171 C;
    7,8-dichlorop-4-dimethyl ino-1-ethyl- (1 2.4) triazole (4.3 - ") quinoxaline, methanesulfonate, t. Pl. 216-219 C;
    4-acetylamino-1-ethyl-8-fluoro- (1, 2.4) triazole (4, 3-o) quinoxaline, so pl. 203-205 sJ
    4-amino-7-chloro-1-ethyl- (1,2,4) triazole (4, 3-o) quinoxaline, methanesulfonate, m.p. 240-243 ° C;
    7-chloro-1-ztsh1-4-ethylamino- (1,2,4,) triazole (4,3-) quinox alin, methane sulfonate, t, pl. 187-189 ° C;
    7-chloro-4-diethylamino- (1,2,4) triazole (4, 3- ") quinoxaline, methanesulfonate. m.p. 205-207 0;
    . 4 diethylamino-7,8-difluoro- (1,2, 4) triazole (4,3-a) quinoxaline, methanesulfonate, t. Pl. 220-223 ° C, 4-acetylamino-7-chloro-1-ztil- (1, 2.4) triazole (4.3-0) quinoxaline, so pl. 210-212 ° C;
    17
    8-chloro-1-ethyl-4-ethylamino (1,2 4) triazole {4,3-c |) quinoxaline, methanesulfonate, t. Pl. 235-38 C;
    4-amino-7-chloro- (1,2,4) triazole (45 3-o) quinoxaline, methanesulfonate, m.p. 279-282 ° C;
    4-amino-8-chloro-1-methyl- (1,2,4) triazole (4,3-a) quinoxaline, methanesulfonate, t, pl. 213-215 C;
    8-hl, -4-isopropylamino-1-trifluoromethyl- (1,2,4) triazole (4,3-l) quinoxaline, methanesulfonate, m.p. 183-185 ° C .; ,
    8-hys. P-4-diethylamino-1-methyl- (1, 2.4) triazole (4,3-c) quinoxaline, methane-;
    ten
    sulfonate, so pl. 172-175 ° C;
    4-diacetylamino- (1,2,4) triazole (4, 3-a) quinoxaline, square 2.11-214 ° C;
    4-diacetylamine-8-chloro- (1,2,4) triazole (4,3-i) quinoxaline, m.p. 208-210 ° C;
    8-chloro-4-isopropylamino-1-methyl- - (1,2,4) triazole (4,3-th) quinoxaline, methanesulfonate, t. Pl. 206-208 ° C;
    4-acetylamino-1-methyl-8-chloro- (1, 2.4) triazole (4,3-a) quinoxaline, so pl. 262-264 ° C;
    8-chloro-1-ethyl-4-trimethylacetyl but- (1,2,4) triazole (4,3-m) quinoxaline,. t. Sh1. 211-213 C;
    7,8-difluoro-1-ethyl-4-isopropylamino- (1,2-4) triazole (4,3-a) quinoxaline, methanesulfonate, t. Pl. 151-152 ° C;
    4-n-butyrsh1aminr-8-5sl or-1-ethyl- (1,2,4) triazole (4,3-a) quinoxaline, so pl. 185-187 ° C |
    8-chloro-4-diethylamino-1-trifluoromethyl- (1,2,4) triazole (4,3-a) quinoxaline, hydrate, t. Pl. 135-136 ° C;
    1246895
    8-: lor-4-isopropylamino-1-phenyl- - (1,2,4) triazole (4,3-a) quinoxaline, so pl. 183-186 ° C;
    8-g: ENT-4-ethylamin-1-phenyl- (1,2, 4) triazole (4,3-a} quinoxaline, mp. 254- 256 C;
    . 7-fluoro-4-isopropylamino- (1,2, 4) triazole (4,) quinoxaline, methanesulfonate, m.p. 216-214 C |
    1-ethylamine-7-fluoro- (1,2,4) triazole (4, 3-m) quinoxaline, methanesulfonate, m.p. 216-218 C;
    1-diethylamine-8-fluoro-1-trifluoromethyl- (1,2,4) triazole (4,3-) quinoxaline, m.p. ib-iE C;
    7,8-dichloro-1 ethyl-4-of propylamino- (1, 2.4) triazole (4.3-) quinoxaline, mp. 197-198 ° C;
    8-i1or-4-diethylamine-1-phenyl- (1, 20 2,4) triazole (4,3-a) quinoxaline, so pl. 194-19 5 ° C.
    1-acetylamino-1-ztil-7-fluoro- (1,2, 4) triazole (4,3-a) quinoxaline, mp 277-275 C; 25 I. ,
    1-adhylamine-8-chloro-1-trifluoromethyl- (1,2,4) triazole C4, 3-ct) xynoqucnin, mp. 215-216 ° C .;
    4-amine-8-chloro-1-phenyl- (1,2,4) tria-2Q azole (4,3-a) quinoxaline, methanesulfo 15
    4-amino-8-chloro-1-trifluoromethyl- - (1,2,4) triazole (4,3-c () quinoxaline, methanesulfonate, mp 239-261 C;
    4-eth1amine-8-fluoro-1-trifluoromethyl- (1,2,4) triazole (4,) quinoxaline, methanesulfonate, mp, 180-183 ° C;
    8-fluoro-4-isopropylamino-1-trifluoromethyl- (1,2,4) triazole (4,3-a) quinoxapin, methanesulfonate, m.p. 185-188 seconds; 1
    4-diethylamine-7,8-difluoro-1-ethish- (1, 2.4) triazole (4,3-a) quinoxaline, t. Pl. 109-111 ° C;
    1-ethyl-4-ztilamine-7-fluoro- (1,2,4) triazole (4,3-o) quinoxaline, methanesulfonate, t. Pl. 215-219 C;
    4-amino-7-methoxy- (1,2,4) tria-sol (4,3-) quinoxaline, methanesulfonate, m.p. 262-264 ° C;
    nat, m.p. 273-275 C;
    8-chloro-4-ethylamino-1-trifluoromethyl- - (1,2,4) triazole (4,3-th) quinoxaline, so pl. 228-230 ° C;
    1-ethyl-7-fluoro-4-isopropylamine- (1, 2.4) triazole (4,3-d) quinoxaline, methanesulfonate, so pl. 178-181 ° C;
    4-amine: o-B-fluoro-1-trifluoromethyl- (1, 2.4) triazole (4,3-a) quinoxaline, hydrate, so pl. 260-263 ° C;
    8-chloro-1ZTyl-4R-phenylisopropyl-amino-(, 2.4) triazole (4, 3-o) quinoxaline, so pl. 135-157 ° C;
    4-amino-1-ztil-7-fluoro- (1,2,4) triazole (4,) quinoxapine, m.p. 285-289 ° C;
    40
    50
    4-amino-1-ztil-7-methoxy- (1,2,4) triazole (4,3-th) quinoxaline, methanesulfonate, so pl. 255-258 0;
    4-acetonylamine-8-fluoro-1-trifluoromethyl- (1,2,4) triazole (4,3-) quinoxaline, m.p. 217-219 C;
    4-acetylamino-1-ethyl-7-methoxy- (1, 2.4) triazole (4,3-a) quinoxaline, m.p. 202-205 Ci
    8-chloro-1 ethyl-4-B-phenylisopropyl-amine (1,2,4) triazole (. 4,3-b) quinoxaline, m.p. 1 56-1 57 C;
    4-amine-8-chloro-1-phenyl- (1,2,4) triazole (4,3-a) quinoxaline, methanesulfonate, m.p. 273-275 C;
    8-chloro-4-ethylamino-1-trifluoromethyl- - (1,2,4) triazole (4,3-th) quinoxaline, so pl. 228-230 ° C;
    1-ethyl-7-fluoro-4-isopropylamine- (1, 2.4) triazole (4,3-d) quinoxaline, methanesulfonate, so pl. 178-181 ° C;
    4-amine: o-B-fluoro-1-trifluoromethyl- (1, 2.4) triazole (4,3-a) quinoxaline, hydrate, so pl. 260-263 ° C;
    8-chloro-1ZTyl-4R-phenylisopropyl-amino-(, 2.4) triazole (4, 3-o) quinoxaline, so pl. 135-157 ° C;
    4-amino-1-ztil-7-fluoro- (1,2,4) triazole (4,) quinoxapine, m.p. 285-289 ° C;
    4-amino-1-ztil-7-methoxy- (1,2,4) triazole (4,3-th) quinoxaline, methanesulfonate, so pl. 255-258 0;
    4-acetonylamine-8-fluoro-1-trifluoromethyl- (1,2,4) triazole (4,3-) quinoxaline, m.p. 217-219 C;
    4-acetylamino-1-ethyl-7-methoxy- (1, 2.4) triazole (4,3-a) quinoxaline, m.p. 202-205 Ci
    8-chloro-1 ethyl-4-B-phenylisopropyl-amine (1,2,4) triazole (. 4,3-b) quinoxaline, m.p. 1 56-1 57 C;
    nineteen
    4-adhylamino-8-fluoro (1,2,4) triazole (4,3-) quinoxaline, m.p. 240-242 C;
    4-acetylamino (1,2,4) triazole (4, ..) quinoxaline, m.p. Zby- / Z C;
    4-amino-7-fluoro- (1,2,4) triazole (4, 3 - ") quinoxaline, methanesulfonate, m.p. 246-248 C;
    4-amino-8-fluoro- (1,2,4) triazole (4, 3-a) quinoxaline, methanesulfonate, m.p. 17b-178 C;
    4-acetylamino-7-fluoro- (1,2,4) triazole (4,3-a) quinoxaline, mp. 290-292 ° C;
    8-chloro-4-isopropylamino-1-penta-fluoroethyl- (1,2,4) triazole (4,3-a) quinoxaline, m.p. 171-174 C;
    Example 27. 8-Chloro-1-ETHYL-4-propionylamino- (1,) triazole (4, 3-a and quinoxaline.
    A mixture containing 1.2 g (0.005 mol) of 4-amino-8-chloro-1-ethyl (1,2,4) tr azole (4,3-) quinoxaline (mp. 248-253 C) - product , described in example 32, and 15 ml of propionic anhydride with silica gel (1.5 kg). Column
    yes, refluxed for about 16 hours and then cooled to room temperature (about). After that, the resulting reaction mixture is filtered, and the precipitated precipitate 30 is successively diluted in chloroform. Then this organic solution is filtered and sequentially washed with water, saturated aqueous sodium bicarbonate solution and saturated saline solution, then dried over anhydrous magnesium sulfate. After removing the drying agent by filtration and the solvent, by evaporation under reduced pressure, a residual material is obtained, which is subsequently chromatographed on a column of 150 ml of silica gel and then eluted with a mixture of
    chloroform and collect fractions containing the desired product. These fractions are concentrated under vacuum using a rotary vacuum pump. Thus, 410.2 g of pure 4-diethylamino (1,2, 4) triazolo (4,3-c1) quinoxaline are obtained in the form of a white solid.
    4-Distilamino- (1,2,4) triazolo (4, 35 3-a) quinoxaline (410.2 g; 1.7 mol), prepared as described, is dissolved in hot ethanol (4100 ml). The heat source is then removed and methanesulfonic acid (192.2 g, 2.0 mol) is added to the alcohol solution. The resulting reaction mixture was stirred at room temperature overnight (about 16 hours). At the end of this stage
    40
    4-Distilamino- (1,2,4) triazolo (4 35 3-a) quinoxaline (410.2 g; 1.7 mol) prepared as described, dissolved in hot ethanol (4100 ml). The heat source is then removed and the methanesulfonic acid (192.2 g, 2.0 mol) is added to the alcohol solution. The resulting reaction mixture was stirred at room temperature overnight (approximately 16 hours). At the end of this stage
    chloroform and methanol (95: 5 by volume is filtered to remove the residue). Equal fractions containing
    the fallen product, which is sequentially washed with fresh ethanol, then dried in air to constant weight. In this way
    the product is combined and then concentrated in vacuo to obtain a crystalline material, which, after recrystallization from a mixture of chloroform and distil ether, finally gives 540 mg (36%) of pure 8-chloro-1-ethyl-4-propionyl 1 in (1, 2 ,, 4) triazole (4,3- “) quinoxaline, so pl. 211-215 ° C.
    Calculated,%: C 55.36; - H 4.64; N 23.06. C ,, H.ClNjO
    24689520
    Found,%: C 54.91; H 4.59 ;:
    N 22.76.
    PRI me R 28. 4-Distilamino- (1, 2.4) triazole (4,3-e) quinoxaline mesylate, 5 A mixture of 4-chloro (1,2,4) triazole (4,3-th) quinoxalin (556 g, 2.7 mol), the product of example 2, diztilamine (830 mp; 8.1 mol) and K, N-dimethylformamide (3 l) are stirred with a mechanical membrane with a cap at room temperature; the temperature of the resulting reaction The mixture gradually increases until a dark green solution is obtained, which is then stirred at room temperature for four days. The treated reaction mixture is poured onto ice, after which the crude product precipitates, which is collected by suction filtration and well washed with water. The crude product is dissolved in chloroform, filtered and the resulting product is reduced in volume by evaporation under vacuum. After that, the product is placed on
    chloroform and collect fractions containing the desired product. These fractions are concentrated under vacuum using a rotary vacuum pump. Thus, 410.2 g of pure 4-diethylamino (1,2, 4) triazolo (4,3-c1) quinoxaline are obtained in the form of a white solid.
    4-Distilamino- (1,2,4) triazolo (4, 3-a) quinoxaline (410.2 g; 1.7 mol), prepared as described, is dissolved in hot ethanol (4100 ml). The heat source is then removed and methanesulfonic acid (192.2 g, 2.0 mol) is added to the alcohol solution. The resulting reaction mixture was stirred at room temperature overnight (about 16 hours). At the end of this stage
    the mixture is filtered to extract the
    the mixture is filtered to extract the
    the fallen product, which is sequentially washed with fresh ethanol, then dried in air to constant weight. In this way,
    503 g of crude product as a salt are obtained. Recrystallization of this product from ethanol (4000 ml) gives 412 g (49%) of pure 4-dieth-1-amino (1,2,4) triazolo (4,2-) quinoxALIN methanesulfonate (methylate), m.p. 211-214 ° C.
    EXAMPLE 29 A test used to detect high-speed antidepressant activity in rats is a modification of the well-known Porsolt method using an objective set method developed by Wallach and Hadley of mice. Just as by a known method. Porsolt, male Spreg-Dawley rats weighing 280 - 325 g each are individually placed in plastic cylinders (45 cm high and 22 cm in diameter) with water at 25 ° C and at a height of water column 25 cm.
    On the first day, the rats are placed in these cylinders with water, where they are allowed to swim for 15 minutes. for the first ten minutes, the rats usually swim in circles around the pool walls, looking for a way to get out. By the end of the fifteen-minute period, understand that it is impossible to choose, the animals remain stationary and so lie down until they collapse. 24 h after such an experiment, a binder or test compound was orally administered to ten rats, and then, usually an hour later, they were put back into their pools. A mixture containing 90 vol.% Saline (0.9%), aqueous sodium chloride, 5 vol% ethanol and 5 vol% emulphor is used as a binder.
    The compounds receive, by dissolving or suspending, the test compound in ethanol and emulphorus, followed by dilution with physiological saline. Two minutes after immersion, the rats are treated with the preparations, each 30 ° C is evaluated from the viewpoint of their behavior directed towards. something to choose from the pool. A total of 30 observations were made. If the rat remains stationary and lies passively on the surface of the water, it is evaluated by 1 for immobility. If a rat tries to get out of the pool (vigorously / swims or dives), it is given a rating of O. All rats are evaluated in this way for 30 s.
    Thus, on the basis of a series of 10 observations, a rat that remains completely immobile during the whole trial receives a score, and a rat that keeps itself restless trying to get out of the bath receives a lower score. Usually the rats treated by the breeding animals show an average rating.
    8 - 9 while antidepressant treatment reduces this immobility (i.e. counteracts despair or hopelessness) depending on dose and degree of chronicity. Under these conditions, a compound is considered active if the response between the animals treated with the drug and the control group (i.e., animals receiving a single binder) are considered statistically significant compared with results obtained using standard anti-depressive methods such as KEM sleep deprivation and electroconvulsive. In other words, a compound is considered active if a statistically significant decrease in immobility is recorded.
    Accordingly, (1,2,4) triazolo (4,3-a) quinoxaline-4-amine derivatives are tested for rapid antidepressant activity in rats using the well-known Porsolt method. The compounds were found to be active when administered orally in the dosages indicated in the table, moreover, if X, X, R. ,, R and R are hydrogen, then such a compound described by Draykorn can be used as an agent for combating pyriculosis of rice).
    The compounds are administered orally in the form of one or more doses of 0.1-100 mg / kg body weight per day, preferably 0.5-10 mg / kg per day. For parenteral or intravenous administration, these compounds are administered in doses of 0.1-10 mg / kg of animal body weight per day. However, if necessary, the dosage can be changed depending on the condition of the animal to be treated and the type of compound used.
    Toxicity data
    LDj-d 1-ethyl-4-ethylamino- (1,2, 4) tri.azolo (4,3-c ") quinoxaline for male M5 mice - 600-800 mg / kg when administered orally.
     1 Ethyl 4-ethylamino- (1,2,4) tr azolo (4,3-p) quinoxaline for males less than 100-200 mg / kg when administered intraperitoneally.
    LDfo of 1-ethyl-4-ethylamine- (1,2, 4) triazolo (4, 3-o) quinoxaline for female mice is 200-400 mg / kg for oral administration.
    23
    LDsfl 1-ethyl-4-ethyl-dano- (1,2,
    CV
    124689524
    male mice - 100 - 150 mg / kg with
    4) .RiZolo (4W.Zhinoksalina dL sam- fnZ- -Hs rp n aMHHo-Cl, 2. We have 200-600 mg / kg for the first, J, 1 °,), „„ o , halitus for oral administration, .., male necks - 200–400 mg / kg with pento-1-ethyl-4-ethylamino- (1.2, 5 males
    4) triazolo (4,3-a) kinoksalina for ° Tfluor 4 isopropyl p.o- (1.2, male rats - 60–150 mg / kg with inner 1 f J;, „„
    tribalonin administration. zoh z oTmg to at
    LD, o 1-ethyl-4-ethylamino- (1.2, male rats - 300– 500 mg / kg at 4) triazolo (4,3-a) quinoxaline for saa 10 oral administration.
    Moist rats - 100-400 mg / kg with feathers. " ,/ about
    Raline., LD, "8-fluoro-4-isopropylamino- (1,2,
    Toxicological data. 4) triazolo (4,3-sec.) Hinoquine saline for LDfo 8-fluoro-4-isopropylamino- (1,2-rat males- 100-150 mg / kg with; 4) triazolo (4,3-a) quinoxaline for a me- 15 intraperitoneal injection. K-male-400-600 mg / kg with LD, 8-fluoro-4-isopropylamino- (1, oral, ee. 2,4) triazolo (4,3-sec.) Quinoxaline
    LDjfl 8-fluoro-4-isopropylamino- (1,2, male rats - 100–300 mg / kg with 4) triazolo (4,3-a) quinoxaline for oral administration. - -HIN.N
    i-r W
    X-4A.f NR2R3
    124689524
    male mice - 100 - 150 mg / kg with
    权利要求:
    Claims (4)
    [1]
    The method of obtaining derivatives of (1.2.4) triazole (4,3-a) quinoxaline-4-amine of the general formula 1:
    where X and X 4 are each selected from the group consisting of hydrogen, fluorine, chlorine, bromine or a methoxy group;
    R 5 is hydrogen, lower alkyl, trifluoromethyl or phenyl;
    R z and R ^ are each selected from the group consisting of hydrogen, lower alkyl, · Phenylalkyl having from 1 to 3 carbon atoms in the alkyl part, and alkanoyl having from 2 to 5 carbon atoms, provided that at least one of the radicals R 2 and R ^ is always different from hydrogen when X and X, each is hydrogen and R, is hydrogen or methyl, or R and R 3 taken together form a piperazine ring, or their salts, distinguishing n d 'I 6 so that the corresponding 4-chloro derivative (1.2 / 1) the triazole (4,3 *) quinoxaline total .Formuly II wherein X, and X 4 have the abovementioned meaning, are mutually Procedure with an excess of between three and saturated 'of the amine of general formula III hnr 2 3 where r R. and R 3 have the indicated meanings, in addition to alkanoyl, in an inert organic solvent at 0 - 58 ° C for 2 to 18 hours and, if necessary, further a compound of general formula 1, where one of R and R 3 is hydrogen, is reacted with the corresponding alkanoic anhydride acid in an inert anhydrous organic solvent at a temperature from room temperature to 140 ° C for 3 to 18 hours to form a compound of general formula 1, where R and R 3 each is alkanoyl, and the desired product is isolated in free form or in the form of a salt.
    [2]
    2. The method according to p. 1, characterized in that in the reaction
    00 Ph of the amination with an inert organic solvent is Ν, Ν is dimethylformamide.
    >
    sya
    [3]
    3. The method according to π. 1, with the fact that acylation is carried out at a molar ratio of alkanoic acid anhydride and 4-amino ~ compound from 4: 1 to 25: 1, respectively.
    [4]
    4. The method according to π. 1, the fact that in the acylation reaction an inert anhydrous organic solvent is a halogenated hydrocarbon solvent.
    类似技术:
    公开号 | 公开日 | 专利标题
    US4719047A|1988-01-12|Anthracene derivatives
    KR100812586B1|2008-03-13|Quinazoline compounds useful as p38 kinase inhibitors
    JPH0737460B2|1995-04-26|Pyranoindolizine derivative and method for producing the same
    KR20050061490A|2005-06-22|Process and intermediates for the preparation of thienopyrrole derivatives
    DK161327B|1991-06-24|SUBSTITUTED 2-PIPERAZINOPTERIDINES, PROCEDURES FOR PREPARING THEREOF, AND MEDICINALS CONTAINING THE COMPOUNDS
    SU1487814A3|1989-06-15|Method of producing 7-amino-3-/3-|-1-propene-1-yl/-3-cephem-4-carboxylate
    US5221681A|1993-06-22|Substituted benzoxazepines and benzothiazepines
    EP0369145B1|1995-12-27|Pyrrolo[3,2-e]pyrazolo[1,5-a]pyrimidine derivatives and medicines comprising the same
    SU969165A3|1982-10-23|Process for producing condensed pyrimidines, or their salts, or their optical isomers
    SU1246895A3|1986-07-23|Method of producing |triazobenzene|quinoxaline-4-amine derivatives or salts thereof
    BG99359A|1995-11-30|Tetracyclic compounds, method and intermediate compounds for their preparation and their application as antitumour compositions
    FI78084C|1989-06-12|FOERFARANDE FOER FRAMSTAELLNING AV NYA, TERAPEUTISKT VERKSAMMA BENSOPYRANDERIVAT.
    SU999973A3|1983-02-23|Process for producing derivatives of pyrido|pyrimidine or their pharmaceutically acceptable salts or their optically active isomers
    SU930902A1|1982-10-15|Derivatives of thieno|indole
    Tam et al.1979|Synthesis of C-Nucleosides. 17. s-Triazolo [4, 3-a] pyrazines
    US4495187A|1985-01-22|Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents
    JP2000504352A|2000-04-11|Pyrrolo [3,2-c] quinoline derivatives containing haloalkoxy groups and pharmaceutically acceptable salts thereof
    KR900008840B1|1990-11-30|Process for the preparation of substituded 7-oxomitosane
    CA1173445A|1984-08-28|Quinolone derivatives and their use aspharmaceuticals
    EP0107455B1|1986-07-09|Triazoloquinoxalines as antidepressants and antifatigue agents
    JP2815150B2|1998-10-27|Substituted dibenzocycloheptenimine
    JP2991348B2|1999-12-20|7- | oxy-9a-methoxymitosan and its production and use
    US4677108A|1987-06-30|4-oxo-pyrido[2,3-d]pyrimidinone derivatives
    US4167569A|1979-09-11|Pyrimido[1,2-a ]benzimidazole derivatives
    US4547501A|1985-10-15|Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents
    同族专利:
    公开号 | 公开日
    NZ205986A|1986-06-11|
    PH19080A|1985-12-19|
    PT77507A|1983-11-01|
    JPS5989684A|1984-05-23|
    IN160956B|1987-08-22|
    NO160142B|1988-12-05|
    FI74011B|1987-08-31|
    YU43331B|1989-06-30|
    FI74011C|1987-12-10|
    YU207483A|1986-02-28|
    FI833781A0|1983-10-17|
    FI833781A|1984-04-19|
    CS248711B2|1987-02-12|
    JPH039915B2|1991-02-12|
    PL244194A1|1985-03-26|
    GR78952B|1984-10-02|
    ES526533A0|1985-04-01|
    ZA837691B|1985-05-29|
    DD215545A5|1984-11-14|
    NO160142C|1989-03-15|
    CA1207772A|1986-07-15|
    PL141382B1|1987-07-31|
    NO833770L|1984-04-24|
    KR840006485A|1984-11-30|
    PT77507B|1986-05-28|
    KR860001493B1|1986-09-27|
    ES8504197A1|1985-04-01|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    RU2552114C2|2010-09-16|2015-06-10|Хатчисон Медифарма Лимитед|Condensed heteroaryls and their application|US4008322A|1975-06-10|1977-02-15|Eli Lilly And Company|Triazoloquinoxalines for control of rice|JP4707261B2|2001-05-15|2011-06-22|日本エンバイロケミカルズ株式会社|Quinoxaline compound and industrial bactericidal composition|
    JP4529535B2|2004-04-30|2010-08-25|住友化学株式会社|Bactericidal use of 4-amino [1,2,4] triazolo [4,3-a] quinoxaline compounds|
    ES2536906T3|2006-12-13|2015-05-29|Aska Pharmaceutical Co., Ltd.|Quinoxaline derivative|
    TW201024297A|2008-09-10|2010-07-01|Kalypsys Inc|Heterocyclic inhibitors of histamine receptors for the treatment of disease|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US43477182A| true| 1982-10-18|1982-10-18|
    [返回顶部]